| __timestamp | HUTCHMED (China) Limited | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 26684000 | 5078000000 |
| Thursday, January 1, 2015 | 29829000 | 4717000000 |
| Friday, January 1, 2016 | 39578000 | 5096000000 |
| Sunday, January 1, 2017 | 43277000 | 4986000000 |
| Monday, January 1, 2018 | 48645000 | 4214000000 |
| Tuesday, January 1, 2019 | 52934000 | 3806000000 |
| Wednesday, January 1, 2020 | 61349000 | 3671000000 |
| Friday, January 1, 2021 | 127125000 | 3528000000 |
| Saturday, January 1, 2022 | 136106000 | 3445000000 |
| Sunday, January 1, 2023 | 133175999 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This analysis compares the SG&A expenses of Teva Pharmaceutical Industries Limited and HUTCHMED (China) Limited from 2014 to 2023.
Teva, a global leader in generic medicines, has seen its SG&A expenses decrease by approximately 31% over the past decade, from a peak in 2016 to a more controlled level in 2023. This reduction reflects Teva's strategic cost-cutting measures and operational efficiencies.
Conversely, HUTCHMED, a prominent player in innovative therapeutics, has experienced a significant increase in SG&A expenses, growing nearly fivefold since 2014. This rise underscores HUTCHMED's aggressive expansion and investment in research and development.
This comparison highlights the contrasting strategies of these two pharmaceutical giants, offering insights into their financial health and strategic priorities.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and HUTCHMED (China) Limited
Comparing SG&A Expenses: argenx SE vs HUTCHMED (China) Limited Trends and Insights
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Genmab A/S
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Dr. Reddy's Laboratories Limited
SG&A Efficiency Analysis: Comparing Teva Pharmaceutical Industries Limited and Ascendis Pharma A/S
Teva Pharmaceutical Industries Limited vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Xenon Pharmaceuticals Inc.
R&D Insights: How Teva Pharmaceutical Industries Limited and HUTCHMED (China) Limited Allocate Funds
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Arrowhead Pharmaceuticals, Inc.
HUTCHMED (China) Limited and MannKind Corporation: SG&A Spending Patterns Compared